Stephen H. Thorne
Chief Tech/Sci/R&D Officer at Kalivir Immunotherapeutics, Inc.
Stephen H. Thorne active positions
| Companies | Position | Start | End |
|---|---|---|---|
Kalivir Immunotherapeutics, Inc.
 Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Director/Board Member | - | - |
| Chief Tech/Sci/R&D Officer | - | - |
Career history of Stephen H. Thorne
Statistics
International
| United States | 2 |
Operational
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Health Technology |
- Stock Market
- Insiders
- Stephen H. Thorne
- Experience